Susan Kilsby to succeed Matthew Emmens as Chairman

Susan Kilsby to succeed Matthew Emmens as Chairman of Shire Dublin, Ireland - January 23, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) todayannounces that Matthew Emmens will retire as Non-Executive Chairman and SusanKilsby, Chairman of Shire's Audit, Compliance & Risk Committee will succeed himafter the conclusion of Shire's AGM on 29 April 2014. Matt joined the company as Chief Executive in 2003 and became Chairman of Shirein 2008. During his more than ten year tenure at Shire, the Company has grownsubstantially, and now has a broad-based portfolio of products for specialistand rare conditions marketed around the world as well as a diverse and valuablepipeline of treatments in development. Susan Kilsby joined the Shire Board as a Non-Executive Director in September2011 following a distinguished global career in investment banking. In May 2013she was appointed Chairman of Shire's Audit, Compliance & Risk Committee. Upon becoming Chairman of the Board, Susan will step down as Chairman ofShire's Audit, Compliance & Risk Committee. At that time, Dominic Blakemorewill become Chairman of that Committee. It is also announced that Susan will become a member of Shire's NominationCommittee with effect from 1 February 2014. David Kappler, Deputy Chairman, Senior Independent Non-Executive Director andChairman of Shire's Nomination Committee said: "On behalf of all the Board, I would like to thank Matt Emmens for his manycontributions to Shire during the last decade. Susan will build on the strongcurrent Board dynamics and will make an excellent Chairman." Matthew Emmens, Shire Chairman commented: "I have thoroughly enjoyed my ten-plus years with Shire. The Company hasdeveloped so much during this time and it continues to thrive and grow. Havingworked with Susan on the Board over the past few years I believe she is theideal Chairman for Shire as the Company embarks on another new era of growth." For further information please contact: Investor Relations Eric Rojas [email protected] +1 781 482 0999 Sarah Elton-Farr [email protected] +44 1256 894157 Media Jessica Mann [email protected] +44 1256 894 280 Gwen Fisher [email protected] +1 484 595 9836 NOTES TO EDITORS Susan is also a Non-Executive Director of BBA Aviation plc, Coca-Cola HBC AGand Green Mountain Coffee Roasters Inc. Susan has served as a part-time SeniorAdvisor to Credit Suisse Group AG since 2009 and this role will conclude whenshe becomes Chairman. Earlier in her career, during her more than 30 years at Credit Suisse, sheserved as Chairman of Mergers & Acquisitions, EMEA and Vice Chairman of theEuropean Investment Banking Committee, and also led the European Consumer,Retail & Services Investment Banking Group. Her career in global investmentbanking also includes senior positions with Barclays de Zoete Wedd, BankersTrust and The First Boston Corporation. She serves as the International Regional Chair of the Committee of 200 and wasa founding Member of the Competitor Diversity Forum. She is a Visiting Fellowof the Cass Business School and is Chairman of the M&A Research Centre at Cass.Susan also serves on the Advisory Board of the Yale School of Management and isa Member of the Business Leadership Council of Wellesley College. An American national with UK citizenship, Susan gained her first degree inEconomics at Wellesley College and her MBA at Yale School of Management. Shehas homes in the US and in Europe. About Shire Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal andInternal Medicine and we are developing treatments for symptomatic conditionstreated by specialist physicians in other targeted therapeutic areas. www.shire.com Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX Press Release www.shire.com